Monopar Therapeutics Inc.

NASDAQ:MNPR

Biotechnology

Healthcare
$70.75 +2.45%

+$1.58 today

Market cap
$479.46M
Beta
1.54
P/E (TTM)
-37.6
EPS (TTM)
-$1.76
52W Low $29.18High $105.00

Volume 0.10M

Average 0.17M

MNPR Total Assets

Everything the company owns or controls; equal to total liabilities plus equity.

Monopar Therapeutics Inc.NASDAQ: MNPR

Total Assets · Q1 FY2026 · quarter ended Mar 2026

Total assets rises 150.5% from a year ago

Total assets stood at $137.98M at the end of Q1 FY2026, up 150.5% from a year earlier and down 1.9% from the prior quarter. Over 3 fiscal years it compounded at +119.9% a year.

Context

  • Total assets increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total assets keeps rising in the next quarterly balance sheet after a +150.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$137.98M-1.9% QoQ
Last fiscal yearDec 2025
$140.72M+133.4% YoY
Year agoMar 2025
$55.09M+150.5% since
Total Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+150.5%——
1 year+133.4%——
3-year CAGR+119.9%——
5-year CAGR——
10-year CAGR——

Total Assets history

USD · from the balance sheet

Latest · FY2025
140.72M USD
Year-over-year change
+133.4%
4-year CAGR
+61.8%

Total Assets vs competitors

How MNPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +150.5% is the 2nd highest of 11, against a peer median of +2.0%.
  • Over three fiscal years its annual growth of +119.9% compares with a peer median of -8.5%.
MNPR Competitors
Total Assets for MNPR and competitors
Company Period Latest balance YoY 3-year CAGR
ZYMEZymeworks Inc.Sep 2026$1.18B USD+196.1%-18.9%
XNCRXencor, Inc.Jun 2026$724.96M USD-17.6%+1.1%
BCYCBicycle Therapeutics plcMar 2026$652.4M USD-26.2%+20.5%
IMNMImmunome, Inc.Sep 2026$505.53M USD+68.9%+205.1%
ADCTADC Therapeutics S.A.Mar 2026$291.5M USD+7.0%-13.0%
MGNXMacroGenics, Inc.Mar 2026$217.87M USD-3.0%-3.9%
CMPXCompass Therapeutics, Inc.Mar 2026$205.17M USD+56.1%+3.2%
ALXOALX Oncology Holdings Inc.Mar 2026$178.33M USD+47.5%-42.2%
MNPRMonopar Therapeutics Inc.Mar 2026$137.98M USD+150.5%+119.9%
IPHAInnate Pharma S.A.Dec 2025€62.69M EUR-43.6%-32.9%
ATNMActinium Pharmaceuticals, Inc.Jun 2026$40.16M USD-36.3%-23.2%
Peer median (excluding MNPR) —+2.0%-8.5%

Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents20.3M8.19M7.27M45.82M61.83M
Short-term Investments04.93M014.4M78.57M
Net Receivables00000
Inventory00000
Other Current Assets217.75K45.98K66.43K78.87K63.75K
Total Current Assets20.52M13.17M7.33M60.29M140.46M
Property, Plant & Equipment (Net)061.23K12.65K0254.92K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00000
Total Non-current Assets061.23K12.65K0254.92K
Total Assets20.52M13.23M7.35M60.29M140.72M
Account Payables1.58M3.13M1.76M2.25M2.74M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00000
Total Current Liabilities1.58M3.13M1.76M5.25M2.74M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities08.41K00154.92K
Total Liabilities1.58M3.14M1.76M5.25M2.89M
Common Stock12.6K12.95K14.91K6.1K6.69K
Retained Earnings(41.29M)(51.8M)(60.21M)(75.79M)(89.51M)
Accumulated OCI(3.16K)8.94K(14.13K)35.99K131.39K
Other Stockholders Equity00000
Minority Interest00000
Total Equity18.94M10.09M5.59M55.04M137.83M
Total Debt08.41K00154.92K
Net Debt(20.3M)(8.18M)(7.27M)(45.82M)(61.68M)

Monopar Therapeutics Inc.

NASDAQ:MNPR

Intrinsic Alpha fair value

Locked

Current Price

$70.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.